A Phase 1 Study of MLN8237 in Japanese Patients with Relapsed and/or Refractory Non-Hodgkin's lymphoma

Takeda Pharmaceutical Company Limited0 个研究点目标入组 24 人开始时间: 2012年5月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with relapsed and/or refractory Non-Hodgkin's Lymphoma that is diagnosed hisologically or cytologically
•2) Patients with radiologically or clinically measurable diseases
•3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1

•1) Prior treatment with Aurora kinase inhibitors
•2) Prior treatment of allogeneic hematopoietic stem cells transplant, or organ transplant
•3) Patients with brain or cerebrospinal invasion
•4) Major surgery within 14 days prior to enrollment
•5) Serious infection or infection that requires intravenous antibiotics within 14 days prior to enrollment.
•6) Simultaneously diagnosed with or treated for another malignancy, or having a clinical history of primary malignancy in another organ(s)

发起方